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It is with great interest that I read the 
Article by Thomas Van Boeckel and 
colleagues,1 reporting global  antibiotic 
consumption. It is quite concerning 
that two-thirds of the increase in 
antibiotic usage between 2000 and 
2010 occurred in BRICS countries 
(Brazil, Russia, India, China, and South 
Africa). As Van Boeckel and colleagues 
explain, this problem is partly due 
to the population increase in these 
countries, better access to drugs, and 
the improved socioeconomic status 
of BRICS countries. The absence of 
functioning antibiotic policies has 
fostered indiscriminate antibiotic use 
and misuse in most BRICS countries. 
The large increase in cephalosporin and 
fluoroquinolone consumption in India 
and China is particularly noteworthy, 
but is not unexpected as long as a 
course of these antibiotics is cheaper 
than a culture and sensitivity report. A 
large population size, socioeconomic 
disparity, and heterogeneity within 
the health-care system in most BRICS 
countries are major impediments for 
strict implementation of antibiotic 
policies.
Yet the highest use of antibiotics per 
person is in the USA, a country with 
good socioeconomic status that does 
not have the usual excuses for antibiotic 
misuse that developing countries have. 
The USA is also the country with the 
highest level of antibiotics misuse in 
veterinary practice.2 Antibiotic usage 
in Australia and New Zealand has 
also increased over the same period. 
The publication of Van Boeckel and 
colleagues’ Article coincided with 
a meeting between BRICS leaders 
in Brazil. If this coincidence was 
orchestrated with the good intention of 
mobilising political will in BRICS leaders, 
the authors should be congratulated. 
In the war against microbes, the end 
justifies the means.
This is an opportunity for BRICS 
countries to consider the situation 
carefully. At the same time, the world 
should take an uncritical approach, as 
India did with the Chennai declaration.3 
This set of recommendations produced 
a serious change in the way the issue 
of antibiotics resistance is perceived 
by the medical community and 
authorities in India. The 5 year plan4 
proposed by the Chennai declaration is 
an ideal template for the improvement 
of infection control and standard of 
antibiotic stewardship in developing 
countries. Even developed countries, 
such as the USA, might benefit 
from similar initiatives (eg, World 
Alliance against Antibiotic Resistance, 
Antibiotic Action, and ReAct) to 
reduce antibiotic usage in medical and 
veterinary practice.
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We applaud Thomas Van Boeckel 
and colleagues1 for their large 
analysis of antibiotic consumption in 
71 countries. A 36% increase in use of 
antibiotics worldwide, 76% of which 
was in Brazil, Russia, India, China, and 
South Africa, is a concerning finding. 
In Europe and the USA, practitioners 
are increasingly aware of the 
importance of infection control and 
antimicrobial stewardship. How ever, 
50% of anti microbials, irrespective of 
setting, are used inappropriately.2,3 We 
agree that most increases in global 
antibiotic con sumption are probably 
caused by inappropriate use and 
that coordinated efforts to improve 
antimicrobial use internationally are 
desperately needed.1,2  
Several European countries have 
instituted national campaigns to 
en courage appropriate use of anti-
microbials.1 In the USA, antimicrobial 
stewardship programmes have been 
recommended across all facets of 
health care, including acute, long-
term, and ambulatory-care centres.3,4 
However, California is the only state 
with formal state-wide legislation 
that supports anti microbial steward-
ship.5 Although legislation is an 
important first step in the promotion 
of anti microbial steward ship, staffing 
con straints, limited funding and 
admini strative sup port, and other 
barriers to stewardship still persist.5  
Formal legislation that mandates 
stewardship does not exist in other 
US states, but Rhode Island has 
adopted a state-wide approach to 
over come stewardship barriers. 
Hospital administration, public 
health agencies, and multi disciplinary 
health-care providers from various 
practice settings are collaborating to 
advance antimicrobial stewardship 
efforts in the state. Providers 
from settings with established 
programmes assist those without 
established programmes. In May, 
2011, the Rhode Island Antimicrobial 
Stewardship Task Force  was formed 
to allow pharmacists from each of 
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collaborate towards the advancement 
of antimicrobial stewardship through 
monthly leader-facilitated meetings, 
development of treatment pathways, 
dosing guidelines, example policies, 
and educational material, and sharing 
of ideas and experience of hospital 
barriers and facilitators of anti-
microbial stewardship. The Infection 
Control Professionals of Southern 
New England is an infec tion-
control collaborative that promotes 
education, collaboration, and best 
practice for the prevention and 
control of infections. The Rhode Island 
Department of Health has convened 
a Task Force for Antimicrobial 
Stewardship and Environmental 
Infection Control, which has provided 
recommendations for environmental 
cleaning in Rhode Island hospitals and 
long-term care facilities. All groups 
work together to improve regulation 
of antimicrobial use in the state.
With the alarming increase in 
antimicrobial use worldwide, efforts 
are urgently needed to prevent 
un necessary antimicrobial con-
sumption. Multidisciplinary groups 
should come together to promote 
the adoption and expansion of 
antimicrobial stewardship. State-
wide collaboration focused on 
antimicrobial stewardship might 
be an effective means to improve 
utilisation of antimicrobials, which 
could be adopted by other states and 
regions worldwide. 
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excellent saftey profile and without 
adverse effects.4 
Most of these trials (22 of 24) 
were done in high-income countries 
and in this setting probiotics had 
no significant effect on late-onset 
sepsis, a common complication of 
preterm birth, affecting up to 50% of 
the most immature infants (infants 
born before 28 weeks gestation; RR 
0·91, 95% CI 0·80–1·03).4 By contrast, 
trials of probiotics done in resource-
poor and emerging settings show 
a significantly reduced incidence of 
bacterial and fungal late-onset sepsis 
in very low birthweight infants.5–7 The 
benefits of probiotics in resource-poor 
settings are supported by a trial in a 
community setting in India in 2013 
(n=4556), in which low birthweight 
infants (weighing >2000g) were 
given Lactobacillus plantarum and 
the prebiotic fructo-oligosaccharide, 
resulting in a significant reduction in 
serious infections (sepsis, pneumonia, 
and diarrhoea) during the first 60 days 
of life (personal communication).8 
The reported reductions in late-
onset sepsis caused by probiotic 
supplementation are probably affected 
by the gestational age and birthweight 
of the infants, the local pattern of 
invasive patho gens, the pathogen’s 
antibiotic sus ceptibilities, and the type 
of probiotic strain or strains used.
In view of the global burden of 
preterm and very low birthweight 
infants with invasive infection and 
the increasing numbers of multidrug-
resistant microorganisms, probiotics 
have much potential in resource-
poor settings as a simple, safe, and 
affordable public health intervention. 
Additional research is essential to 
address the present gaps in knowledge 
on probiotics for treating preterm and 
low birthweight infants, especially in 
the context of resource poor settings. 
In view of the cost associated with 
the import, storage, and distribution 
of proven probiotic strains, future 
randomised controlled trials could 
compare the efficacy and safety of 
proven strains with that of local 
Probiotics to prevent 
early-life infection
Anna Seale and colleagues1 reported 
estimates of possible severe bacterial 
infec tion in neonates in resource-
limited settings. Worldwide about 
15 million infants are born preterm 
each year and about 1 million of 
them die in infancy.2 Additionally, 
roughly 18 million in fants are born 
with low birthweight, pre dominantly 
in low-income and middle-income 
countries. This population has a high 
burden of morbidity and mortality 
associated with invasive infections in 
the neonatal period and early infancy.3 
Despite partial success in improvement 
of childhood mortality as part of WHO 
millenium goals, neonatal and early 
infant mortality has remained mostly 
unchanged since 2000.3
A review by Alfaleh and colleagues in 
2014 (24 randomised trials, n=5000) 
supports that enteral probiotic sup-
plementation significantly reduces 
necrotising enterocolitis (relative 
risk [RR] 0·43, 95% CI 0·33–0·56) and 
all-cause mortality (RR 0·65, 95% CI 
0·52–0·81) in very low birthweight 
infants (weighing <1500g), with an 
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